M&A / Deals Merck to buy Terns in $6.7B bet on a ‘differentiated’ leukemia drug BioPharma DiveIf consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix.M&A / DealsHematologyRead full story pharminent March 25, 2026 (Last updated: March 25, 2026) BioPharma Dive If consummated, the deal would hand Merck a treatment that could challenge Novartis fast-selling Scemblix. M&A / DealsHematologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Karyopharm myeloma drug yields mixed data in myelofibrosis trialNext: Sarepta sees early success with RNAi drugs from Arrowhead Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
